Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. - Wikidata - wikimedia - TriplyDB

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

http://www.wikidata.org/entity/Q33391788

about

Current Trends of Renal Impairment in Multiple Myeloma European perspective on multiple myeloma treatment strategies in 2014 Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange.The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation.Multiple myeloma treatment strategies with novel agents in 2011: a European perspective A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?Bortezomib for previously untreated multiple myeloma.Bortezomib for previously untreated multiple myeloma.Management of myeloma-associated renal dysfunction in the era of novel therapies.Novel approaches for reducing free light chains in patients with myeloma kidney.Current treatments for renal failure due to multiple myeloma.Kidney disease and multiple myeloma.International Myeloma Working Group recommendations for global myeloma care.Current strategies for treatment of relapsed/refractory multiple myeloma.Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney).Managing renal complications in multiple myeloma.Current treatments for renal failure due to multiple myeloma.Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years.'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: incidence, treatment and outcome.Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model.Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era.Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.Bortezomib for the treatment of multiple myeloma.Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report.Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.

P2860

Q26740444-E0FD8468-A7F1-4F9E-9896-607645AE5F18 Q27005966-91B7613F-A66C-4E32-ACC5-D36DB195350E Q33407105-20BBF093-4ABA-4B41-A38A-0CC8E7EF40AF Q33408056-FB5F55C3-05F7-400B-8ADA-3783929630E4 Q33418712-8BFF2EB3-3935-4C27-ADFF-CA53539A8A9B Q33442039-CBE63BC7-266B-4E3C-B61A-AC4C01259B5C Q33558161-0C99733D-F1D4-4407-8DA9-1F25E258B4C9 Q33622292-E2E7C18A-9592-403C-AC0F-AEA105F9A1D8 Q33864162-DA9FC27F-27DE-456F-BB59-A89D599AFA23 Q34666924-F6DFD9BD-0DCA-4A49-B77D-5D40547EA917 Q35012436-4E0B2E55-EC05-42CA-8D88-E2C4C046251D Q35244883-DB2DEA27-2F04-4C9D-9C90-4D57CB31FC55 Q36010511-30834109-EDA5-481F-8F9B-0865FD399BA4 Q37375516-36AB763E-A248-495F-8425-7C6E6AD13E62 Q37694425-57256FE3-A244-4A04-913E-E2563EB08996 Q37858327-F2B31154-3277-4B5A-8B3C-8677A637CF84 Q37903590-8C7E424A-4A79-417E-B8C0-53D8EF726AB8 Q37908155-7047EA55-EB4C-46A8-A15F-3658C946148C Q37937699-C1D3E227-E99E-4B95-A146-D1104B569170 Q37978343-701036CE-C5CD-4DE2-AF6A-3427E15A8808 Q37986358-2273B7BF-38EA-41D7-A8F9-883850E81375 Q38109235-2F5520B9-35FF-4B7A-8B2A-30BA808EF672 Q38122674-40F6AEF2-8041-4690-AD25-22331292E85D Q38157532-F9BF5262-2FD5-4377-BD7F-6423D3C29E4B Q38182683-0E5DDD6A-0BBE-4CFF-8A75-12C1A962E20A Q38650700-95286C68-7162-4A20-9C9E-BC09E4CFE3B8 Q38802354-AE350830-1B71-4300-8C19-1846FBE1DF08 Q38900024-4E4D7DCC-1929-4DE2-A1C1-DDDA56589D0F Q38959138-71AB3AAE-BBE9-4345-885C-EB725E3A9F27 Q40395165-1F4BFFE8-A0B9-4BC7-B2B5-70DA1DC75689 Q40582501-58A716ED-E7BD-46B3-9C84-98B6A682FE3A Q40779803-C22319F2-3C6E-4FF1-82CE-ADD97669F1DB Q42136161-838E03A7-435B-4A87-AB5B-05449D01676B Q42318234-D50C6AEC-5ABE-4700-8967-E9D186D97BA8 Q42573839-AFA5C3B8-D3E7-40B8-BCEC-CFEF08DDBD4F Q47162496-71496D2C-67F8-436D-861F-62EEE2D4EC14 Q47604607-115F39C9-6BC3-4374-92B1-FAF62B9362D8 Q49199576-59238642-A61E-45D4-989B-EE0A51B7B802 Q50055765-2C35C044-AD61-40ED-A6F2-33CE2188286E Q50089740-1FCF9A8E-4294-46A1-8C86-6470986CD33E

P2860

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

http://www.wikidata.org/entity/Q33391788

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Light chain-induced acute rena ...... : results of a phase II study.

@ast

Light chain-induced acute rena ...... : results of a phase II study.

@en

type

label

Light chain-induced acute rena ...... : results of a phase II study.

@ast

Light chain-induced acute rena ...... : results of a phase II study.

@en

prefLabel

Light chain-induced acute rena ...... : results of a phase II study.

@ast

Light chain-induced acute rena ...... : results of a phase II study.

@en

P1433

Q33391788-62676C19-288A-4906-B2AB-0A48F7A339B9

P1476

Q33391788-C575A558-6403-480E-80AC-4BE9A2C704AD

P2093

Q33391788-0528C307-0E5C-427C-B755-506CDDE61132

Q33391788-060E2ABB-7ED6-40FD-9ABF-0DD9405344C0

Q33391788-413A8720-3D33-4944-BD3B-81058059E423

Q33391788-41B3573D-B969-48F2-BA0F-CE4C8EBD8B43

Q33391788-5316D58A-E70C-4A69-BAF7-A4961DF40C52

Q33391788-6036345C-2272-4778-BECA-D5A848E1B144

Q33391788-68E7456A-24E6-4827-9E8B-9D4B0F0F8108

Q33391788-6EF7FAD6-5455-46D7-A35B-70381D9E6F4A

Q33391788-75BF6E7B-1194-4C93-B7E8-9EE370C920D4

Q33391788-DBA06575-8EE0-4ADE-8029-52FF6CB84D0A

P304

Q33391788-AC8A005E-5CFD-4851-8C44-FCD65E6F7FF4

P31

Q33391788-D3759A4B-B9C2-4606-8D5E-DDCA0C771C86

P356

Q33391788-070F983C-FD11-4B85-9DE2-C3A6FE7A4D58

P407

Q33391788-F7DC161D-2A74-41C5-AD99-994706E0005D

P433

Q33391788-51577657-65EA-4BB0-BF9C-EECE9BC64F9F

P478

Q33391788-0354BBC7-5194-4DE5-AA42-2B993ABFBF31

P50

Q33391788-4A583A14-49F9-4754-A234-1264D8B3F661

Q33391788-7D2F1F29-AD7A-44CA-A795-730719E2E58C

P577

Q33391788-30A711E5-FBF3-442B-A56B-0279388F2356

P698

Q33391788-5CA1A105-46A9-47EF-A4CA-C60DC95B2E11

P921

Q33391788-89E9AAB4-7375-47C7-BB23-CD27876893BE

P356

JCO.2010.28.1238

P1433

Journal of Clinical Oncology

P1476

Light chain-induced acute rena ...... a: results of a phase II study

@en

P2093

Alois Lang

http://www.w3.org/2001/XMLSchema#string

Elena Tóthová

http://www.w3.org/2001/XMLSchema#string

Eva Maria Autzinger

http://www.w3.org/2001/XMLSchema#string

Felix Keil

http://www.w3.org/2001/XMLSchema#string

Heinz Gisslinger

http://www.w3.org/2001/XMLSchema#string

Irene Womastek

http://www.w3.org/2001/XMLSchema#string

Josef Thaler

http://www.w3.org/2001/XMLSchema#string

Miklós Egyed

http://www.w3.org/2001/XMLSchema#string

Niklas Zojer

http://www.w3.org/2001/XMLSchema#string

Richard Greil

http://www.w3.org/2001/XMLSchema#string

P304

4635-4641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.28.1238

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20823423

http://www.w3.org/2001/XMLSchema#string

P921